pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. Having spent 10 years working in the genomics field, Del Bourgo noticed manufacturers spending extensive resources on drug development without harnessing the transformative power of data.

Immunity 105

Immunity Immunization Drug Development Vaccines 105

pharmaphorum

NOVEMBER 19, 2021

The race to find and bring vaccines to market to fight Covid was impressive. So too are the sales figures. Pfizer/BioNTech’s vaccine dominates the market. billion in vaccine sales this year. Together, these mRNA jabs have an iron grip on the covid vaccine market – in the US, they have consolidated a 90% market share.

Vaccines 137

Vaccines Communication 137

Proxsys Rx

NOVEMBER 15, 2023

That said, here is one fundamental issue we haven’t previously discussed: Optimizing the quality and number of your 340B eligible contract pharmacies The simple truth is, we’ve never served (or seen) a 340B health system with adequate in-house resources to do just that.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Independent Pharmacies 52

Proxsys Rx

FEBRUARY 15, 2024

That said, here is one fundamental issue we haven’t previously discussed: Optimizing the quality and number of your 340B eligible contract pharmacies The simple truth is, we’ve never served (or seen) a 340B health system with adequate in-house resources to do just that. We know of one TPA that charges 30¢ for every attempt.

Specialty Pharmacies 40

Specialty Pharmacies Hospitals Independent Pharmacies 40

PharmaShots

APRIL 13, 2023

The idea was coined by the ISPE to integrate discrete aspects like resources, organization & processes, culture, and information systems. Such as inclination towards the Pharma 4.0 Such as inclination towards the Pharma 4.0 Some of the significant transformations carried out to bolster biopharma industries are: Adapting to Pharma 4.0

Biosimilars 40

Biosimilars Vaccines Pharmaceutical Companies Pharmaceutical Companies 40

Digital Pharmacist

NOVEMBER 21, 2022

A policy being finalized by CMS will require Part D plans to add any price reductions they obtain from network pharmacies to the negotiated price at the time of sale, allowing the beneficiary to benefit from the savings as well. b) Marketing and Communications Oversight. Resources: [link] [link] [link] [link] [link].

Communication 98

Communication Documentation Pharmacy Management Immunity 98

PharmaShots

MAY 1, 2023

A factor that distinguishes every company from the others is human resources. Despite putting in efforts, resources, and time, often drugs fail to make it to the approval stage, incurring heavy losses. the adoption of recent technologies that require specialists to handle, and most importantly the current market trends.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Diabetes Vaccines 40

PharmaShots

MAY 1, 2023

A factor that distinguishes every company from the others is human resources. Despite putting in efforts, resources, and time, often drugs fail to make it to the approval stage, incurring heavy losses. the adoption of recent technologies that require specialists to handle, and most importantly the current market trends.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Diabetes Vaccines 40

PharmaShots

MAY 9, 2023

The article briefly elaborates on the six major factors that every pharma company should assess to scale up and ace the market and introduces an efficacious model to keep frequent checks on the factors. Moreover, dietary awareness amongst the general public has spiked owing to IoTs, indirectly influencing the sales of vitamin supplements.

Pharmaceutical Companies 56

Pharmaceutical Companies Pharmaceutical Companies Drug Development Drug Pricing 56

Pharmaceutical Technology

SEPTEMBER 26, 2022

The plan is for Sandoz to continue [to] supply key products to Novartis for distribution in certain key global health markets, primarily in sub-Saharan Africa.” . While Novartis would have preferred another sale for Sandoz, it continues on its march towards solely concentrating on innovative drug development and sales.

Biosimilars 64

Biosimilars Drug Development Vaccines Dosage 64

pharmaphorum

NOVEMBER 17, 2021

In this blog, PRISYM ID’s Clinical Trials Sales Manager Bob Bowdish looks at the challenges of in-sourcing label management processes for CDMOs, and explores how they can be overcome by investing in a cloud-based, validation-ready labeling solution. Stick or twist? Growing pains: the perceived barriers to in-sourcing label management.

Labelling 52

Labelling 52

Viseven

JULY 11, 2023

Organizations can use pre-built integrations to simplify credentialing, while an intuitive dashboard will help them optimize contracting activities. With an advanced lead nurturing system, sales and marketing professionals can engage with the right prospects by delivering the right message at the right time.

Health and Personal Care Stores 40

Health and Personal Care Stores Insurance Coverage and Processing Scheduling Appointments Communication 40

pharmaphorum

MAY 6, 2022

Sanofi has completed the spin-out of its pharma ingredients business EuroAPI, with shares in the new company rising more than 3% on its starting price of €12 in early trading on the Euronext exchange this morning in a declining market. The post Sanofi ingredients spin-out EuroAPI rises on market debut appeared first on.

64

64

pharmaphorum

JULY 9, 2021

Buying Vectura is a very different move, billed by PMI as a way to “leverage its capabilities in life sciences, product innovation, and clinical expertise” It also signposts a long-term strategic shift for PMI as it faces declines in tobacco smoking in big markets that are not being replaced by a shift to nicotine vapes.

Compounding 52

Compounding 52

pharmaphorum

AUGUST 12, 2021

” “Stakeholders could benefit from PMI’s significant financial resources and its intentions to increase research and development investment and to operate Vectura as an autonomous business unit that will form the backbone of its inhaled therapeutics business,” it added.

52

52

Pharma Marketing Network

JUNE 8, 2020

This is Don Langsdorf with the Pharma Marketing Network pleased to welcome today Dave Chase, co-founder of the Health Rosetta. There’s what I call the real market and so this market really exploded, and I have data in this chapter about it. In that market, the real Market, my view prices have been flat for 5 to 10 years.

Health and Personal Care Stores 40

Health and Personal Care Stores Hospitals Mayo Clinic Specialty Pharmacies 40